Antagonists of PD-1 and PD-L1 in Cancer Treatment

Evan J. Lipson, Patrick M. Forde, Hans Joerg Hammers, Leisha A. Emens, Janis M. Taube, Suzanne L. Topalian

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

PD-1 pathway, comprising immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in tumor microenvironment. Drugs designed to block PD-1 or PD-L1 "release brakes" on anti-tumor immunity and have demonstrated clinical activity in several types of advanced cancers, validating this pathway as a target for cancer rapy. Two such drugs have recently been approved to treat melanoma and lung cancers, and regulatory approvals in first- and second-line settings for additional cancer types are anticipated. manageable safety profile of PD-1/PD-L1 blocking drugs identifies m as suitable for outpatient administration and development of combinatorial rapies. Ongoing studies aim to identify biomarkers to guide patient selection, which would furr improve risk:benefit ratio for se drugs.

Original languageEnglish (US)
Pages (from-to)587-600
Number of pages14
JournalSeminars in Oncology
Volume42
Issue number4
DOIs
StatePublished - Jan 1 2015

Fingerprint

Pharmaceutical Preparations
Programmed Cell Death 1 Receptor
Neoplasms
Tumor Microenvironment
Therapeutics
Immunosuppression
Patient Selection
Immunity
Melanoma
Lung Neoplasms
Outpatients
Biomarkers
Odds Ratio
Ligands
Safety

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Lipson, E. J., Forde, P. M., Hammers, H. J., Emens, L. A., Taube, J. M., & Topalian, S. L. (2015). Antagonists of PD-1 and PD-L1 in Cancer Treatment. Seminars in Oncology, 42(4), 587-600. https://doi.org/10.1053/j.seminoncol.2015.05.013

Antagonists of PD-1 and PD-L1 in Cancer Treatment. / Lipson, Evan J.; Forde, Patrick M.; Hammers, Hans Joerg; Emens, Leisha A.; Taube, Janis M.; Topalian, Suzanne L.

In: Seminars in Oncology, Vol. 42, No. 4, 01.01.2015, p. 587-600.

Research output: Contribution to journalArticle

Lipson, EJ, Forde, PM, Hammers, HJ, Emens, LA, Taube, JM & Topalian, SL 2015, 'Antagonists of PD-1 and PD-L1 in Cancer Treatment', Seminars in Oncology, vol. 42, no. 4, pp. 587-600. https://doi.org/10.1053/j.seminoncol.2015.05.013
Lipson, Evan J. ; Forde, Patrick M. ; Hammers, Hans Joerg ; Emens, Leisha A. ; Taube, Janis M. ; Topalian, Suzanne L. / Antagonists of PD-1 and PD-L1 in Cancer Treatment. In: Seminars in Oncology. 2015 ; Vol. 42, No. 4. pp. 587-600.
@article{65e1a4043b094833b15aa2dfac3477c6,
title = "Antagonists of PD-1 and PD-L1 in Cancer Treatment",
abstract = "PD-1 pathway, comprising immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in tumor microenvironment. Drugs designed to block PD-1 or PD-L1 {"}release brakes{"} on anti-tumor immunity and have demonstrated clinical activity in several types of advanced cancers, validating this pathway as a target for cancer rapy. Two such drugs have recently been approved to treat melanoma and lung cancers, and regulatory approvals in first- and second-line settings for additional cancer types are anticipated. manageable safety profile of PD-1/PD-L1 blocking drugs identifies m as suitable for outpatient administration and development of combinatorial rapies. Ongoing studies aim to identify biomarkers to guide patient selection, which would furr improve risk:benefit ratio for se drugs.",
author = "Lipson, {Evan J.} and Forde, {Patrick M.} and Hammers, {Hans Joerg} and Emens, {Leisha A.} and Taube, {Janis M.} and Topalian, {Suzanne L.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1053/j.seminoncol.2015.05.013",
language = "English (US)",
volume = "42",
pages = "587--600",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Antagonists of PD-1 and PD-L1 in Cancer Treatment

AU - Lipson, Evan J.

AU - Forde, Patrick M.

AU - Hammers, Hans Joerg

AU - Emens, Leisha A.

AU - Taube, Janis M.

AU - Topalian, Suzanne L.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - PD-1 pathway, comprising immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in tumor microenvironment. Drugs designed to block PD-1 or PD-L1 "release brakes" on anti-tumor immunity and have demonstrated clinical activity in several types of advanced cancers, validating this pathway as a target for cancer rapy. Two such drugs have recently been approved to treat melanoma and lung cancers, and regulatory approvals in first- and second-line settings for additional cancer types are anticipated. manageable safety profile of PD-1/PD-L1 blocking drugs identifies m as suitable for outpatient administration and development of combinatorial rapies. Ongoing studies aim to identify biomarkers to guide patient selection, which would furr improve risk:benefit ratio for se drugs.

AB - PD-1 pathway, comprising immune cell co-receptor Programmed Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates local immunosuppression in tumor microenvironment. Drugs designed to block PD-1 or PD-L1 "release brakes" on anti-tumor immunity and have demonstrated clinical activity in several types of advanced cancers, validating this pathway as a target for cancer rapy. Two such drugs have recently been approved to treat melanoma and lung cancers, and regulatory approvals in first- and second-line settings for additional cancer types are anticipated. manageable safety profile of PD-1/PD-L1 blocking drugs identifies m as suitable for outpatient administration and development of combinatorial rapies. Ongoing studies aim to identify biomarkers to guide patient selection, which would furr improve risk:benefit ratio for se drugs.

UR - http://www.scopus.com/inward/record.url?scp=84929342210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929342210&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2015.05.013

DO - 10.1053/j.seminoncol.2015.05.013

M3 - Article

C2 - 26320063

AN - SCOPUS:84929342210

VL - 42

SP - 587

EP - 600

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4

ER -